Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
This protein carries a polyhistidine tag at the C-terminus.
The protein has a calculated MW of 16.8 kDa. The protein migrates as 20-26 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to different glycosylation.
>95% as determined by SDS-PAGE.
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
Human CD69, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95% (With Star Ribbon Pre-stained Protein Marker).
Emerging VoCs, Omicron, Delta, Beta, Alpha mutants and so on, including RBD, S trimer, S1, NTD, NP, etc. These mutants are of high purity and bioactivity and can be used to evaluate the efficacy of the antibodies and vaccination.
ACROBiosystems developed a series of GMP grade cytokines under the GMP grade quality management system. Those products are all suitable for T/NK cell generation, activation, and proliferation in cell therapy research.
50+ targets designed for CAR detection, including PE/FITC/biotin labeled proteins. The key reagents for CD19 and BCMA were FDA DMF filed which can support your IND, NDA and BLA process.
GMP grade cytokines, reagents for cell activation, gene edition, DNA/RNA removal, etc. Particularly focus on product design, quality control and solution-based support to link each phase of your cell and gene therapy journey.
Full length multi-pass TPs with stabilized structure and high bioactivity for immunization, antibody screening, cell based assay and CAR detection, including hot CD20, Claudin 18.2, CD133, GPRC5D,CCR8, CCR5, etc.
CD3 proteins and a collection of for bispecific antibody development which are of high specificity and bioactivities and suitable for immunization, antibody screening.
A series of immune checkpoints including classic co-inhibitory and co-stimulatory receptors. The comprehensive catalog contains 100+ targets with various species and tags, and the high-quality proteins are in good batch-to-batch consistency.
To meet the needs of ADCs development, ACROBiosystems can provide: A variety of high-quality target proteins; MMPs/Cathepsin/uPA for cleavable linker; Anti-payload antibodies & anti-idiotypic antibodies for immunogenicity and PK analysis; SPR/BLI analytical and ADA development service.
Comprehensive collection of Fc receptor proteins, including their common variants, which can help expedite your antibody development.
The MABSOL biotinylated protein collection includes more than a hundred commonly studied drug targets and biomarker proteins.
Comprehensive cytokines including IL families, growth factors, chemokines, TNFs, etc. These products are HEK293 expressed and nearly in authentic structure, high purity and bioactivity, cell based assay/SPR/BLI verified.
To support preclinical/clinical immunogenicity and PK analysis, ACROBiosystems has developed a series of high-affinity anti-idiotypic antibodies. Our pipeline covers five hot targets including adalimum*b, rituxim*b, cetuxim*b, trastuzum*b, and bevacizum*b.
English Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
---|---|---|---|---|---|---|---|---|---|---|
Triclabendazole | EGA-230B; CGA-89317; NVP-EGA230 | Approved | Novartis Pharma Ag | Egaten, Fasinex, Triclathera | United States | Fascioliasis | Novartis Pharma Ag | 1989-01-01 | Fascioliasis | Details |
Decitabine/Cedazuridine | ASTX-727; E-7727/decitabine; Decitabine/E7727 | Approved | Astex Pharmaceuticals Inc | Inqovi | United States | Myelodysplastic Syndromes | Otsuka Pharmaceutical Co Ltd | 2020-07-07 | Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Solid tumours; Leukemia; Myeloproliferative Disorders; Leukemia, Myelomonocytic, Chronic; Myelodysplastic Syndromes; Neoplasms; Triple Negative Breast Neoplasms; Breast Neoplasms; Leukemia, Myeloid, Acute; Glioma; Nervous System Neoplasms; Neurilemmoma | Details |
Mecobalamin | E-0302 | Approved | Myelogen, Naso B12, NASOCOBAL, Methycobal, 弥尔神, 悦敏兴, RHINOCOBAL, 奇信, 曲力, 弥可保 | Peripheral Nervous System Diseases; Autistic Disorder; Neuralgia; Neuritis; Vitamin B 12 Deficiency; Amyotrophic Lateral Sclerosis; Fibromyalgia | Details | |||||
Decitabine | DAC; AzadC; E-7373; 5-aza-CdR; NSC-127716 | Approved | Eisai Co Ltd | 达珂, Dacogen | EU | Leukemia, Myeloid, Acute | Janssen-Cilag International Nv | 2006-05-02 | Burkitt Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Breast Neoplasms; Neuroblastoma; Primary Myelofibrosis; Colorectal Neoplasms; Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Lymphoma; Urinary Bladder Neoplasms; Lung Neoplasms; Thyroid Neoplasms; Precancerous Conditions; Myelodysplastic-Myeloproliferative Diseases; Carcinoma, Non-Small-Cell Lung; Leukemia, Lymphocytic, Chronic, B-Cell; Neoplasm Metastasis; Thyroid Cancer, Papillary; Breast Neoplasms, Male; Melanoma; Anemia, Sickle Cell; Lymphoma, Large B-Cell, Diffuse; Solid tumours; Leukemia; Purpura, Thrombocytopenic, Idiopathic; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Liver Neoplasms; Leukemia, Myeloid, Accelerated Phase; Leukemia, Promyelocytic, Acute; Esophageal Neoplasms; Thalassemia; Neutropenia; Myelodysplastic Syndromes; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Large-Cell, Immunoblastic; Plasmacytoma; Small Cell Lung Carc | Details |
Azacitidine | NSC-102816; 5-aza-CR; CC-486; NS-17; U-18496; NEX-18; NEX-18a | Approved | Celgene Corp | 维达莎, Vidaza, Onureg | United States | Leukemia, Myeloid, Acute | Celgene Corp | 2004-05-19 | Leukemia, Myeloid, Acute; Immune System Diseases; Prostatic Neoplasms; Tuberculosis, Pulmonary; Breast Neoplasms; Osteosarcoma; Sarcoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Brain Neoplasms; Primary Myelofibrosis; Hepatic Insufficiency; Multiple Myeloma; Lymphoma; Lung Neoplasms; Leukemia, Myelomonocytic, Juvenile; Thyroid Neoplasms; Lymphoma, Non-Hodgkin; Carcinoma, Non-Small-Cell Lung; Myelodysplastic-Myeloproliferative Diseases; Melanoma; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Large Granular Lymphocytic; Myelodysplastic Syndromes; Head and Neck Neoplasms; Intestinal Neoplasms; Solid tumours; Hematologic Neoplasms; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid; Ependymoma; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Leukemia, Myelomonocytic, Chronic; Leukemia; beta-Thalassemia; Lymphoma, Large B-Cell, Diffuse; Plasmacytoma; Myeloproliferative Disorders; Neoplasms; Nasopharyngeal Neoplasms; Small Cell Lung Carcinoma; Glioblastoma; Hodgkin Disea | Details |
English Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
FdCyd | NSC-48006; Ro-5-1090 | Phase 2 Clinical | City Of Hope National Medical Center, National Cancer Institute | Head and Neck Neoplasms; Esophageal Neoplasms; Neoplasms; Myelodysplastic Syndromes; Urinary Bladder Neoplasms; Mesothelioma; Breast Neoplasms; Lung Neoplasms; Leukemia, Myeloid, Acute; Carcinoma, Non-Small-Cell Lung | Details |
Azacitidine/Cedazuridine | ASTX-030 | Phase 3 Clinical | Otsuka Pharmaceutical Co Ltd | Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Myelodysplastic Syndromes; Leukemia, Myeloid, Acute | Details |
Decitabine/Tetrahydrouridine | EPI-01 | Phase 2 Clinical | Epicdestiny | Anemia, Sickle Cell | Details |
Curcumin | VOLT-03; VOLT-3; NSC-32982 | Phase 3 Clinical | University Of Pennsylvania | Renal Insufficiency, Chronic; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prostatic Neoplasms; Breast Neoplasms; Oral Submucous Fibrosis; Tobacco Use Disorder; Cardiovascular Diseases; Cognitive Dysfunction; Neuralgia; Colorectal Neoplasms; Cervical Intraepithelial Neoplasia; Uterine Cervical Dysplasia; Cigarette Smoking; Asthma; Chronic Periodontitis; Lung Neoplasms; Lichen Planus, Oral; Adenocarcinoma, Mucinous; Inflammation; Osteoarthritis; Uterine Cervical Neoplasms; Aortic Aneurysm, Abdominal; Leukemia, Lymphocytic, Chronic, B-Cell; Carcinoma, Non-Small-Cell Lung; Crohn Disease; Adenocarcinoma; Neoplasm Metastasis; Macular Degeneration; Neoplasms; Drug-Related Side Effects and Adverse Reactions; Adenomatous Polyposis Coli; Optic Atrophy, Hereditary, Leber; Digestive System Diseases; Depression; Non-alcoholic Fatty Liver Disease; Diabetes Mellitus, Type 2; Gastritis, Atrophic; Radiodermatitis; Pain; Spasm; Rectal Neoplasms; Atherosclerosis; Primary Dysautonomias; Arthritis, Rheumatoid; Spondylitis, An | Details |
Guadecitabine Sodium | SGI-110; S-110; 0RB89YH367 (UNII code) | Phase 2 Clinical | Otsuka Holdings Co Ltd | Klatskin Tumor; Adenocarcinoma; Paraganglioma; Carcinoma, Non-Small-Cell Lung; Melanoma; Carcinoma, Hepatocellular; Gallbladder Neoplasms; Fallopian Tube Neoplasms; Lung Neoplasms; Leukemia, Myeloid, Acute; Gastrointestinal Stromal Tumors; Colorectal Neoplasms; Peritoneal Neoplasms; Cholangiocarcinoma; Ovarian Neoplasms; Prostatic Neoplasms, Castration-Resistant; Pancreatic Neoplasms; Carcinoma, Transitional Cell; Small Cell Lung Carcinoma; Myeloproliferative Disorders; Myelodysplastic Syndromes; Leukemia, Myelomonocytic, Chronic; Stomach Neoplasms; Carcinoma, Renal Cell; Pheochromocytoma; Kidney Neoplasms; Chondrosarcoma | Details |
EF-009 | EF-009 | Phase 2 Clinical | Everfront Biotech Co Ltd | Pancreatic Neoplasms | Details |
NTX-301 | NTX-303 | Phase 2 Clinical | Southern Research Institute, Pinotbio Inc | Solid tumours; Neoplasms | Details |
This web search service is supported by Google Inc.